
    
      TARGET-IV NA trial is a prospective, multicenter, 1:1 randomized (FirehawkÂ® vs. 2nd
      generation DES), trial.

      Sub studies:

      Angiographic sub study: The first approximately 200 consecutive consenting patients will be
      enrolled in the angiographic substudy. Optical coherence tomography (OCT) substudy: The first
      approximately 50 consecutive consenting subjects will be enrolled in the OCT substudy.

      Clinical follow-up will be performed at 30 days, 6 months, and 1, 2, 3, 4, and 5 years post
      randomization. First approximately 200 consecutive consenting patients will undergo planned
      angiographic follow-up at 13 months after enrollment, with first 50 of these patients also
      consented to undergo planned OCT at baseline and at 13 months following randomization.
    
  